A. Piera

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

J. Baselga, K. Venkatakrishnan, J. Tabernero, 2012, Clinical Cancer Research.

Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors

F. J. Ramos, E. Wiemer, J. Baselga, 2013, Clinical Cancer Research.

A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors

J. Tabernero, C. Michie, C. Kahatt, 2013, Cancer Chemotherapy and Pharmacology.

Cancer Therapy : Clinical See related article by Dehm , p . 6064 Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E 7107 in Patients with Advanced Solid Tumors

F. J. Ramos, E. Wiemer, J. Tabernero, 2013 .

Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma.

J. Baselga, J. Tabernero, J. Smyth, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients with advanced solid tumors.

A. Tolcher, R. Dienstmann, D. Rasco, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P3.02c-063 Lactate Dehydrogenase (LDH) as a Surrogate Biomarker to Checkpoint-Inhibitors for Patient with Advanced Non–Small-Cell Lung Cancer (NSCLC): Topic: IT Biomarkers

E. Felip, A. Navarro, S. Martinez, 2017 .